News
Clinical Trials Arena on MSN14d
Vividion begins subject dosing in trial of RAS-driven cancer treatmentThe therapy is the fourth clinical-stage programme derived from the company’s chemoproteomics discovery platform.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback